ClinicalTrials.gg
Not yet recruitingNCT07869732Updated Oct 9, 2026

(Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty

A Phase 2 interventional study of (Z)-endoxifen in Precocious Puberty, Gonadotropin-dependent, sponsored by Atossa Therapeutics, Inc.. Not yet recruiting at 1 site in United States. Open to female participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Atossa Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 9, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
4 Years to 9 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Puberty, Precocious with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Puberty, Precocious · United States.

Planned enrollment
15th of 15
6 · median 55
Started
2027
the only one that year
Phase 2
5 of 21
1 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
Atossa Therapeutics, Inc.

Among the 21 studies in Puberty, Precocious with a site in United States, this one is the 15th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2027, is one of 5 in phase 2, and was the 21st registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

4 of the 21 studies in Puberty, Precocious with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 4 Years to 9 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Puberty, Precocious with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, and blood levels of (Z)-endoxifen in girls with McCune-Albright Syndrome that have peripheral precocious puberty. The main question it aims to answer [is/are]:

Are there any safety concerns? Is there any evidence of efficacy?

There is no comparison group.

Participants will:

  • take a capsule once a day for 3 months;
  • have doctor visits (tele-health and in-person);
  • blood samples collected; and
  • complete questionnaires
03

Conditions studied

  • Precocious Puberty, Gonadotropin-dependent

Browse trials for

Keywords

  • FD/MAS
  • MAS
  • McCune-Albright
  • McCune Albright
04

Who can participate

Ages eligible
4 Years to 9 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female child aged ≥ 4 to \< 10 years at the time of .
  2. Body weight ≥ 16 kg.
  3. Clinical or molecular diagnosis of McCune-Albright syndrome (MAS), with peripheral precocious puberty and at least one additional characteristic manifestation of MAS other than café-au-lait skin macules, such as polyostotic fibrous dysplasia or another autonomous endocrine manifestation distinct from the participants PPP.
  4. Clinical evidence of gonadotropin-independent (peripheral) precocious puberty, including onset of vaginal bleeding before 8 years of age and recurrent vaginal bleeding documented as at least 2 episodes during the prior 6 months.
  5. Prepubertal or low-normal basal luteinizing hormone (LH) and follicle-stimulating hormone (FSH), consistent with predominantly gonadotropin-independent disease activity.
  6. Advanced bone age, defined as bone age exceeding chronological age by ≥1 year at screening, determined using the protocol-specified standardized radiographic method and central or qualified local reading procedures.
  7. Active peripheral estrogen activity at study entry that, in the Investigator's judgment, is the primary driver of current clinical manifestations.
  8. Ability to swallow small capsules with water. Capsule-swallow training may be provided during screening using non-drug training capsules, or other age-appropriate standard site procedures.
  9. Adequate hepatic, renal, hematologic, and coagulation function based on protocol-defined laboratory criteria.
  10. Parent or legal guardian able and willing to provide written informed consent, with age-appropriate participant assent when applicable.
  11. Participant and parent/caregiver are willing and able to comply with study visits, daily diary completion, study treatment administration, and required procedures.

Exclusion criteria

Exclusion Criteria

  1. Prior bilateral oophorectomy or hysterectomy.
  2. Central precocious puberty (CPP).
  3. The need for the use of GnRH agonists during the trial.
  4. Use of a selective estrogen receptor modulator, aromatase inhibitor, other estrogen-modifying agent, or high-dose progestin within 1 month or 5-half-lives, whichever is longer.
  5. Use of any bone-directed therapies.
  6. Dominant central precocious puberty requiring initiation or intensification of gonadotropin-releasing hormone analog therapy at screening.
  7. uncontrolled endocrinopathy likely to interfere with growth, safety, or interpretation of study outcomes, including uncontrolled hyperthyroidism, growth hormone excess, phosphate-wasting osteomalacia, or Cushing syndrome.
  8. or AST >3 × (ULN), total >2 × ULN, or other clinically significant hepatic impairment at screening (post-letrozole 14 day wash-out), unless the abnormality is explained, stable, and approved by the Sponsor Medical Monitor.
  9. Clinically significant renal impairment, hematologic abnormality, or coagulation abnormality that may increase risk or confound interpretation.
  10. History of venous thromboembolism or known hereditary thrombophilia.
  11. Significant ophthalmic conditions, including cataracts
  12. Known to endoxifen, tamoxifen, or any formulation .
  13. Pregnancy or breastfeeding. Pregnancy testing applies only to post-menarche or otherwise at-risk participants as medically and ethically appropriate.
  14. Participation in another interventional clinical study or receipt of another product within 30 days or 5 half-lives, whichever is longer, before first dose, unless approved by the Sponsor.
  15. Planned major surgery during the 3-month treatment period that could materially affect safety or endpoint assessment.
  16. Any serious concomitant medical, developmental, behavioral, or psychiatric condition that, in the Investigator's judgment, would make participation unsafe, prevent reliable completion of study procedures, or compromise study integrity.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    (Z)-endoxifen arm

    Drug: (Z)-endoxifen

Interventions

  • (Z)-endoxifen will be administered once daily via the oral route

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Incidence, severity, seriousness, and relationship of TEAEs and SAEs; clinically significant changes in laboratory tests, vital signs, ECGs, physical examinations, growth, pubertal development, and other targeted safety parameters.

    Time frame: 3 months

Secondary outcomes

  1. Evaluate patient and family impact (Psycho-social impact) of the early onset of puberty in girls

    This assessment will be determined via validated questionnaires

    Time frame: Prior to and during the study (4 to 5 months)

07

Study locations

1 site
  • NIH
    Bethesda, Maryland 20817, United States
08

References and documents

Individual participant data

Plan to share: Undecided — I am not sure

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Jun 2028, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 9, 2026
StartEst.
Mar 2027
Primary completionEst.
Jun 2028
CompletionEst.
Sep 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07869732
Lead sponsor
Atossa Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Mar 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Alison Boyce, MD
principal investigator · Lasker Clinical Research Scholar Chief, Metabolic Bone Disorders Unit National Institute of Dental and Craniofacial Research National Institutes of Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Endoxifen

Start the discussion